It has been a year of downsizing and restructuring, and the long list of companies that have done so include Hyseq Pharmaceuticals Inc. and Variagenics Inc. Those two slimmed-down companies - one focused on drug discovery and one on diagnostics - said Monday they were merging in a stock deal valued at about $56 million. (BioWorld Today)

It has been a year of downsizing and restructuring, and the long list of companies that have done so include Hyseq Pharmaceuticals Inc. and Variagenics Inc. Those two slimmed-down companies - one focused on drug discovery and one on diagnostics - said Monday they were merging in a stock deal valued at about $56 million. (BioWorld Today)

Novacea Inc. pulled in $36 million in its Series B round of financing, a sum the company says is validated by its drug in a later-stage trial and a solid group at the top. (BioWorld Today)

Novacea Inc. pulled in $36 million in its Series B round of financing, a sum the company says is validated by its drug in a later-stage trial and a solid group at the top. (BioWorld Today)

Zonagen Inc., searching for ways to benefit shareholders for some time, said it is merging with Lavipharm Corp. in a move that should please Zonagen stockholders and fulfill Lavipharm's desire to become a public company. (BioWorld Today)

Zonagen Inc., searching for ways to benefit shareholders for some time, said it is merging with Lavipharm Corp. in a move that should please Zonagen stockholders and fulfill Lavipharm's desire to become a public company. (BioWorld Today)